|
ZNF620 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.0179002085664E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.74309996939337E-09 |
| Normal-vs-Stage2 |
7.367700E-04 |
| Normal-vs-Stage3 |
9.6857000198014E-10 |
| Normal-vs-Stage4 |
5.77780000510231E-08 |
| Stage1-vs-Stage2 |
3.623600E-01 |
| Stage1-vs-Stage3 |
1.185990E-01 |
| Stage1-vs-Stage4 |
2.970800E-01 |
| Stage2-vs-Stage3 |
7.627500E-02 |
| Stage2-vs-Stage4 |
1.443240E-01 |
| Stage3-vs-Stage4 |
8.791200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.41330347004055E-11 |
| Normal-vs-AfricanAmerican |
1.596220E-02 |
| Normal-vs-Asian |
3.66850000044217E-07 |
| Caucasian-vs-AfricanAmerican |
1.009010E-01 |
| Caucasian-vs-Asian |
8.867400E-01 |
| AfricanAmerican-vs-Asian |
1.192790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.95999999563767E-08 |
| Normal-vs-Female |
2.82920020744371E-10 |
| Male-vs-Female |
7.763600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.08279999913685E-08 |
| Normal-vs-Age(41-60Yrs) |
2.14569995105052E-09 |
| Normal-vs-Age(61-80Yrs) |
2.33880000033437E-07 |
| Normal-vs-Age(81-100Yrs) |
8.618500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.723000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.751800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.196800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.526400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.354600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.971200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.171400E-04 |
| Classical-VS-Follicular |
2.128200E-01 |
| Classical-VS-Other |
8.733800E-01 |
| Classical-VS-Normal |
2.59399945967687E-10 |
| Tall-VS-Follicular |
3.603000E-04 |
| Tall-VS-Other |
4.161200E-01 |
| Tall-VS-Normal |
3.81860099096798E-11 |
| Follicular-VS-Other |
6.094200E-01 |
| Follicular-VS-Normal |
1.592540E-04 |
| Other-VS-Normal |
2.077700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.1189000004872E-07 |
| Normal-vs-N1 |
4.68840000156234E-09 |
| N0-vs-N1 |
3.480400E-02 |
|
|
